Axogen Inc (AXGN)

$32.34 +0.58 (1.83%)
Market Cap 1.68B
Revenue (ttm) 225.21M
Net Income (ttm) -15.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6.97%
Debt to Equity Ratio 0.39
Volume 1,076,400
Avg Vol 982,012
Day's Range N/A - N/A
Shares Out 51.90M
Stochastic %K 76%
Beta 0.98
Analysts Strong Sell
Price Target $40.55

Company Profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wra...

Industry: Medical Devices
Sector: Healthcare
Phone: 386 462 6800
Fax: 386 462 6801
Address:
13631 Progress Boulevard, Suite 400, Alachua, United States
dustin1101
dustin1101 Mar. 13 at 2:51 PM
$AXGN Nice morning to make a flip. Sold as high as 33.83. 500 shares there. Added most back near 32.
1 · Reply
dustin1101
dustin1101 Mar. 11 at 11:25 AM
$AXGN 28K in PM volume. Hmmm.
1 · Reply
dustin1101
dustin1101 Mar. 10 at 3:02 PM
$AXGN “Sellers” dried right up.
0 · Reply
dustin1101
dustin1101 Mar. 9 at 2:11 PM
$AXGN 200 more 27.63.. wartime discount.
1 · Reply
Niddi
Niddi Mar. 3 at 5:13 PM
$AXGN Manipulation as usual.
0 · Reply
dustin1101
dustin1101 Mar. 2 at 3:54 PM
$AXGN Adding 30.15
0 · Reply
dustin1101
dustin1101 Feb. 27 at 8:58 PM
$AXGN Diamond bottom on the 15 min chart. Doesn't seem to want to fail the $31 handle.. that's the secondary price which was sold to high (oversized) demand.
0 · Reply
BioGem
BioGem Feb. 25 at 6:46 AM
$AXGN took a short at $34. Many critical negatives: -Revenue is lower quarter over quarter. -Operating expenses are skyrocketing, while bottom line losses are worse with poorer margins. -Dilution of the basic shares is on high gear with millions of new shares dumped in the past year. -Guidance is underwhelming for 2026. -The low growth rate does not warrant at all the current high valuation multiples. A large drop is warranted. -Short interest is creeping up.
1 · Reply
IN0V8
IN0V8 Feb. 24 at 4:08 PM
$AXGN 2/23 Buy Raymond James raises target price to $41 from $36
0 · Reply
erevnon
erevnon Feb. 24 at 3:13 PM
Citizens maintains Axogen $AXGN at Market Outperform and raises the price target from $34 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Latest News on AXGN
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

Mar 6, 2026, 11:15 AM EST - 9 days ago

Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

Axogen Q4: EPS Miss Amid Biologics Transition

Feb 25, 2026, 5:23 AM EST - 18 days ago

Axogen Q4: EPS Miss Amid Biologics Transition

Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 11:37 AM EST - 19 days ago

Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript

First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

Feb 19, 2026, 2:27 PM EST - 24 days ago

First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

BLZE FORM HL JBI KALU MTA OUT

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Feb 17, 2026, 7:00 AM EST - 26 days ago

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 10, 2026, 7:00 AM EST - 4 weeks ago

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Wasatch Micro Cap Fund Q4 2025 Performance Review

Feb 4, 2026, 8:35 AM EST - 5 weeks ago

Wasatch Micro Cap Fund Q4 2025 Performance Review

BLZE CLMB CSTL MAMA VITL

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Jan 21, 2026, 11:18 PM EST - 7 weeks ago

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Axogen Announces Proposed Public Offering of Common Stock

Jan 21, 2026, 4:09 PM EST - 7 weeks ago

Axogen Announces Proposed Public Offering of Common Stock

Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 5:25 PM EST - 2 months ago

Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Jan 12, 2026, 7:00 AM EST - 2 months ago

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 8:01 PM EST - 3 months ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

FDA approves Axogen's nerve repair graft

Dec 3, 2025, 6:53 PM EST - 3 months ago

FDA approves Axogen's nerve repair graft

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Dec 1, 2025, 12:33 PM EST - 3 months ago

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

Nov 5, 2025, 2:19 PM EST - 4 months ago

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

BELFB LMB PMTS WLDN

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 2:26 PM EDT - 4 months ago

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Oct 1, 2025, 12:30 PM EDT - 5 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Oct 1, 2025, 10:50 AM EDT - 5 months ago

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 25, 2025, 6:40 AM EDT - 7 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Aug 12, 2025, 5:17 AM EDT - 7 months ago

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:15 PM EDT - 7 months ago

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:10 PM EDT - 8 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Jul 22, 2025, 4:05 PM EDT - 8 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 10 months ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 3:21 PM EDT - 11 months ago

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

Axogen, Inc. Reports 2025 First Quarter Financial Results

May 8, 2025, 7:05 AM EDT - 11 months ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Apr 24, 2025, 8:04 AM EDT - 11 months ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 1:58 PM EST - 1 year ago

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 25, 2025, 7:10 AM EST - 1 year ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Feb 11, 2025, 4:58 PM EST - 1 year ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 10, 2025, 5:00 PM EST - 1 year ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Jan 6, 2025, 8:01 PM EST - 1 year ago

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 9:53 AM EST - 1 year ago

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 2:10 PM EDT - 1 year ago

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Axogen, Inc. Announces New Leadership Appointments

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jul 1, 2024, 7:00 AM EDT - 1 year ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 28, 2024, 4:30 PM EDT - 1 year ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

May 5, 2024, 1:21 AM EDT - 2 years ago

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

Axogen, Inc Reports First Quarter 2024 Financial Results

May 2, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 29, 2024, 4:50 PM EDT - 2 years ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 11:03 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Mar 5, 2024, 7:00 AM EST - 2 years ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 13, 2024, 4:30 PM EST - 2 years ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

dustin1101
dustin1101 Mar. 13 at 2:51 PM
$AXGN Nice morning to make a flip. Sold as high as 33.83. 500 shares there. Added most back near 32.
1 · Reply
dustin1101
dustin1101 Mar. 11 at 11:25 AM
$AXGN 28K in PM volume. Hmmm.
1 · Reply
dustin1101
dustin1101 Mar. 10 at 3:02 PM
$AXGN “Sellers” dried right up.
0 · Reply
dustin1101
dustin1101 Mar. 9 at 2:11 PM
$AXGN 200 more 27.63.. wartime discount.
1 · Reply
Niddi
Niddi Mar. 3 at 5:13 PM
$AXGN Manipulation as usual.
0 · Reply
dustin1101
dustin1101 Mar. 2 at 3:54 PM
$AXGN Adding 30.15
0 · Reply
dustin1101
dustin1101 Feb. 27 at 8:58 PM
$AXGN Diamond bottom on the 15 min chart. Doesn't seem to want to fail the $31 handle.. that's the secondary price which was sold to high (oversized) demand.
0 · Reply
BioGem
BioGem Feb. 25 at 6:46 AM
$AXGN took a short at $34. Many critical negatives: -Revenue is lower quarter over quarter. -Operating expenses are skyrocketing, while bottom line losses are worse with poorer margins. -Dilution of the basic shares is on high gear with millions of new shares dumped in the past year. -Guidance is underwhelming for 2026. -The low growth rate does not warrant at all the current high valuation multiples. A large drop is warranted. -Short interest is creeping up.
1 · Reply
IN0V8
IN0V8 Feb. 24 at 4:08 PM
$AXGN 2/23 Buy Raymond James raises target price to $41 from $36
0 · Reply
erevnon
erevnon Feb. 24 at 3:13 PM
Citizens maintains Axogen $AXGN at Market Outperform and raises the price target from $34 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 24 at 1:50 PM
$AXGN (-3.9% pre) AxoGen Non-GAAP EPS of $0.07 misses by $0.03, revenue of $59.9M in-line https://ooc.bz/l/94416
0 · Reply
DARKP00L
DARKP00L Feb. 24 at 1:01 PM
$AXGN 07:25 on Feb. 24 2026 CORRECTION: Axogen Sees FY2026 Revenue Of More Than $265.700M vs $259.499M Est #tradeideas
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 24 at 12:11 PM
$AXGN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.28 down -2900.00% YoY • Reported revenue of $59.9M up 21.25% YoY • Axogen expects 2026 full-year revenue growth of at least 18%, reaching $265.7M, with gross margin anticipated between 74% to 76%, and expects to be free cash flow positive.
0 · Reply
LuckEtradER
LuckEtradER Feb. 23 at 10:22 PM
$AXGN 👀
0 · Reply
dustin1101
dustin1101 Feb. 20 at 6:02 PM
$AXGN Umm they're already profitable bub. Or should I say bot?
0 · Reply
dipmilo
dipmilo Feb. 20 at 4:26 PM
$AXGN Axogen develops nerve repair solutions. Growth depends on procedure volumes. Profitability remains a long-term goal.
0 · Reply
dustin1101
dustin1101 Feb. 20 at 4:23 PM
$AXGN Could be the day.. make a hell of a weekly candle.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 5:15 PM
$AXGN Current Stock Price: $35.29 Contracts to trade: $35.0 AXGN Feb 20 2026 Call Entry: $0.35 Exit: $0.55 ROI: 58% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
dustin1101
dustin1101 Feb. 19 at 3:58 PM
$AXGN Any lick of real buy volume and this breaks out. Whenever the big $ decides they are done wringing out shares at these levels…
0 · Reply
erevnon
erevnon Feb. 19 at 2:52 PM
Wells Fargo initiates coverage on Axogen $AXGN at Overweight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
RuleBasedReturns
RuleBasedReturns Feb. 18 at 4:23 PM
$AXGN Axogen develops nerve repair solutions with exposure to surgical procedure volumes. Growth depends on surgeon adoption and reimbursement consistency. Operating leverage improves as utilization scales.
0 · Reply
TheMarketsTheTarget
TheMarketsTheTarget Feb. 18 at 10:45 AM
$AXGN Solid tech Solid company Gap at 18.06. Watching close.
0 · Reply